(Q34531565)

2 August 2017

0 references

1 reference

title

Interferons in relapsing remitting multiple sclerosis: a systematic review (English)

1 reference

relapsing-remitting multiple sclerosis

2 August 2017

0 references

0 references

1 reference

6

1 reference

2 August 2017

5

Chris Polman

1 reference

2 August 2017

Graziella Filippini

1

1 reference

2 August 2017

Luca Munari

2

1 reference

2 August 2017

Barbara Incorvaia

3

1 reference

2 August 2017

George C Ebers

4

1 reference

2 August 2017

George P A Rice

7

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

2 August 2017

1 reference

2 August 2017

361

1 reference

2 August 2017

545-552

1 reference

2 August 2017

9357

1 reference

Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Intrathecal Interferon Reduces Exacerbations of Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Systemic alpha-interferon therapy of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

1 reference

7 January 2021

Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Ingested IFN-alpha: results of a pilot study in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

[Interferon beta 1-a in multiple sclerosis: 1-year experience in 62 patients]

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Interferon-alpha and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. AUSTIMS Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Double blind study of intrathecal beta-interferon in multiple sclerosis: clinical and laboratory results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Clinical trial of natural alpha interferon in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

The effects of long-term administration of recombinant alpha-2 interferon on lymphocyte subsets, proliferation, and suppressor cell function in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Does interferon beta cause initial exacerbation of multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Quality of life as a predictor for change in disability in MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912512-3

7 January 2021

10.1016/S0140-6736(03)12512-3

Identifiers

DOI

1 reference

2 August 2017

1 reference